Recanalization Rate in Patients with Deep Venous Thrombosis on Rivaroxaban Therapy: A Prospective Observational Study at UCMS-TH.

INTRODUCTION Deep venous thrombosis (DVT) is a critical condition with significant morbidity and mortality risks. Direct oral anticoagulants, such as rivaroxaban, have emerged as effective alternatives for DVT management, yet their impact on recanalization rates remains underexplored. MATERIAL AND METHODS A prospective observational study conducted at UCMS Teaching Hospital enrolled 104 patients diagnosed with DVT of both upper and lower limbs from February to September 2024. Duplex ultrasonography assessed thrombus resolution at baseline and after six months of rivaroxaban therapy. This study evaluates the recanalization rates in patients with DVT treated with rivaroxaban using duplex ultrasonography. RESULTS Among 104 patients (41% male, 59% female), 23.8% achieved complete recanalization, 66.7% had partial recanalization, and 9.5% showed residual thrombi. Complete recanalization rates were highest in femoral veins (25.8%) and lowest in popliteal veins (24%). CONCLUSION Rivaroxaban demonstrates favorable recanalization outcomes in DVT patients, supporting its use as first-line therapy. Further studies are needed to optimize treatment and prevent complications like post-thrombotic syndrome.